What is the PHQ‑2 (Patient Health Questionnaire‑2) and how is it used for depression screening?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is the PHQ-2?

The PHQ-2 (Patient Health Questionnaire-2) is an ultra-brief, two-item depression screening tool that asks about depressed mood and loss of interest (anhedonia) over the past two weeks, with each item scored 0-3 for a total possible score of 0-6. 1

Core Components

The PHQ-2 consists of the first two questions from the full PHQ-9 and specifically assesses: 2, 3

  • Depressed mood: "Over the past 2 weeks, have you felt down, depressed, or hopeless?" 1
  • Anhedonia: "Over the past 2 weeks, have you felt little interest or pleasure in doing things?" 1

Each question is scored from 0 ("not at all") to 3 ("nearly every day"), yielding a maximum score of 6. 2

Diagnostic Performance

At a cutoff score of ≥3, the PHQ-2 demonstrates a sensitivity of 73.7% and specificity of 75.2% for detecting major depressive disorder. 1 However, using a lower cutoff of ≥2 increases sensitivity to 86-91% while reducing specificity to 70-78%, capturing more true cases at the cost of more false-positives. 1, 4, 3

The largest validation study in primary care (2,642 patients) found that a PHQ-2 score ≥2 had 86% sensitivity and 78% specificity, while a score ≥3 had 61% sensitivity and 92% specificity. 4 A cutoff of ≥3 is recommended as the optimal threshold for screening purposes. 2, 1

Clinical Implementation: Two-Stage Screening Algorithm

The recommended workflow is to administer the PHQ-2 first as a rapid screen; patients scoring ≥3 should immediately receive the full PHQ-9 to assess severity and guide management. 1, 3 This gated approach requires only 1-2 minutes for the PHQ-2 compared with 3-5 minutes for the PHQ-9, reducing screening burden in busy primary care settings. 1

The two-stage method (PHQ-2 followed by PHQ-9 when positive) maintains similar sensitivity to using the PHQ-9 alone but significantly improves specificity and reduces the number of patients needing to complete the full questionnaire by approximately 57%. 3

Critical Limitation: Suicide Risk Assessment

The PHQ-2 omits the suicide item (item 9 of the PHQ-9), so relying on it alone can miss patients with suicidal ideation who may not endorse the two core depressive symptoms. 1 Consequently, clinicians should never use the PHQ-2 as the sole depression assessment tool and must follow any positive PHQ-2 screen with the full PHQ-9 to capture suicide risk. 1

In high-risk populations or when suicide screening is a priority, start directly with the PHQ-9 rather than the two-stage approach. 1

Implementation Requirements

Effective PHQ-2 screening programs require clear protocols for managing positive results; screening without defined intervention pathways does not improve patient outcomes. 1, 5 Key implementation elements include: 1

  • Designated staff responsibilities for administering and scoring the PHQ-2
  • Established referral pathways to mental health specialists for moderate-to-severe cases
  • Availability of treatment resources for patients who screen positive

Distinction from Other Tools

The PHQ-2 should not be confused with other screening instruments such as the NCCN Distress Thermometer, the Generalized Anxiety Disorder Assessment (GAD-2 or GAD-7), or the Edinburgh Postnatal Depression Scale (EPDS), which are separate tools used for different screening purposes. 6

References

Guideline

Depression Screening and Management Approach

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Patient Health Questionnaire Nomenclature and Usage

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.